Drug maker Mylan Inc. says a subsidiary has started commercial operations in India, beginning with products that treat HIV and AIDS.
Mylan Pharmaceuticals Private Ltd. will initially offer 18 antiretroviral products. The company anticipates adding therapeutic categories and increasing its sales force as its business grows.
India has the world’s third-largest population of people with HIV and AIDS, according to the National AIDS Control Organization.
Mylan already has access to the India market. The Pittsburgh company acquired a majority stake in Matrix Laboratories of India in 2007 and bought the rest of the company in 2009.
Last month Mylan reported stronger-than-expected results in its second quarter, aided by sales of the EpiPen shot for allergic reactions. EpiPen is a pre-filled syringe used to treat severe allergic reactions. It is made by Pfizer Inc., and Mylan holds the U.S. marketing rights.
